Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 16;11:6103–6121. doi: 10.2147/IJN.S112432

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 Li et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Ova-specific CD8⁺ T cells at 6 weeks postpriming.

Notes: (A) Timeline of in vivo treatments. (B) Gating strategy to quantify ova-specific CD8⁺ T cells. Top row from left to right: selection of lymphocyte, selection of single cell to exclude doublets and cell clumps; bottom row from left to right: selection of live cells, exclusion of CD4⁺ cells, B cells, DCs, monocytes, and NK cells, selection of double-positive cells – ova-specific CD8⁺ cells. (C and D) Measurement of ova-specific CD8⁺ T cells from either peripheral blood or spleen by flow cytometry at 6 weeks after priming by IN or IP administration route. Data presented are representative of three mice. (E and F) The absolute number of ova-specific CD8⁺ cells from spleen; each bar represents the value of the average from a group of three mice. *P<0.01.

Abbreviations: DC, dendritic cell; IN, intranasal; IP, intraperitoneal; NK, natural killer; wk, week.

Ova-specific CD8⁺ T cells at 6 weeks postpriming.

Notes: (A) Timeline of in vivo treatments. (B) Gating strategy to quantify ova-specific CD8⁺ T cells. Top row from left to right: selection of lymphocyte, selection of single cell to exclude doublets and cell clumps; bottom row from left to right: selection of live cells, exclusion of CD4⁺ cells, B cells, DCs, monocytes, and NK cells, selection of double-positive cells – ova-specific CD8⁺ cells. (C and D) Measurement of ova-specific CD8⁺ T cells from either peripheral blood or spleen by flow cytometry at 6 weeks after priming by IN or IP administration route. Data presented are representative of three mice. (E and F) The absolute number of ova-specific CD8⁺ cells from spleen; each bar represents the value of the average from a group of three mice. *P<0.01.

Abbreviations: DC, dendritic cell; IN, intranasal; IP, intraperitoneal; NK, natural killer; wk, week.